Global Home Global Home  
 
 

 

 

Investor Relations

Oculus Innovative Science is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries. The company's products are used to treat patients in surgical/advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.  The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. 

PDF Investor Presentation ( 1.4MB)

Recent Releases

May 23, 2013
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2013 Financial Results and Conference Call

May 1, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals for Microcyn®-Based Antiseptic Products in Panama and El Salvador

Apr 24, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals and Target Launch Dates for Three New Microcyn®-Based Products in Middle East Countries

more »

Forward-Looking Statements
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to our product development, success of clinical trials, obtaining the requisite regulatory approvals, market acceptance of our product, our ability to protect our intellectual property and future financial results. For a discussion of other factors that may cause Oculus’ actual results to differ from those projected, expressed or implied by the forward looking statements, please refer to the Company's Registration Statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.